In brief
- The U.S. Department of Defense is funding two clinical trials of MDMA-assisted therapy for PTSD with $9.8 million, targeting active-duty military personnel rather than just retired veterans.
- The official report distinguishes acceptance and commitment therapy at HJF/Walter Reed from massed prolonged exposure at UT Health San Antonio, with Emory as another site. These are not identical protocols.
- The debate extends beyond clinical concerns: several specialists are questioning the logic of treating combat trauma only to return the individual to the front lines that caused it.
An official January 2026 report documents two awards investigating MDMA and military PTSD. The later Science Norway report raises ethical questions about continued service. These are different matters: funding and design establish neither clinical benefit nor return to combat as a measured or achieved outcome.
Two awards and differing designs
The official document identifies $4,899,065 for HJF/Walter Reed and $4,899,999 for UT Health San Antonio, approximately $9.8 million overall. The former plans to integrate MDMA with acceptance and commitment therapy in eighty-six participants. The latter plans massed prolonged exposure in one hundred active, National Guard or Reserve members at UT Health San Antonio and Emory. The report does not establish here that MAPS trains all therapists or that both trials use the same design.
What is known about the design and timeline
The figures 86 and 100 are plans in the January report, not already treated participants. That document said enrollment had not started then. Science Norway described an expected 2027 start, but that media forecast does not verify actual initiation. Operational status for each award has not been reconciled with other registries; general clinical availability or later results are not certified.
What it implies
Research must distinguish symptom relief, autonomy and safety from institutional objectives. Concerns about returning to combat are attributed to specialists interviewed by Science Norway; they do not by themselves establish a protocol requirement. The official report describes research aims and supplies no clinical results from these cohorts. From a harm reduction perspective, participation requires clear information about objectives, procedures, risks and freedom of choice; this report does not establish a return-to-combat requirement.
Source
- Science Norway. “Want to offer MDMA therapy to soldiers with PTSD so they can defend their country for longer”. Science Norway, July 15, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
